Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer

por Zaim, Remziye, Redekop, Ken, Uyl-de Groot, Carin A.
Publicado 2022

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment

por Zaim, Remziye, Redekop, W. Ken, Uyl-de Groot, Carin A.
Publicado 2023

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer

por Zaim, Remziye, Redekop, W. Ken, Uyl-de Groot, Carin A.
Publicado 2023

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

por Ansaripour, Amir, Uyl-de Groot, Carin A., Redekop, W. Ken
Publicado 2017

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

por Xander, Nicolas S. H., Fiets, W. Edward, Uyl-de Groot, Carin A.
Publicado 2023

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry

por Blommestein, Hedwig M., Franken, Margreet G., Uyl-de Groot, Carin A.
Publicado 2015

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory framew...

por van der Gronde, Toon, Uyl-de Groot, Carin A., Pieters, Toine
Publicado 2017

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals

por Polak, Tobias B., van Rosmalen, Joost, Uyl – de Groot, Carin A.
Publicado 2020

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

por Uyl-de Groot, Carin A., Heine, Renaud, Krol, Marieke, Verweij, Jaap
Publicado 2020

Onderdiagnostiek bij kanker door de COVID-19-crisis naar diagnose, leeftijd en provincie: Een cruciale rol voor eerstelijnszorgverleners

por Uyl-de Groot, Carin A., Schuurman, Melinda S., Huijgens, Peter C., Praagman, Jaike
Publicado 2020

Health-related quality of life of multiple sclerosis patients: a European multi-country study

por Visser, Laurenske A., Louapre, Celine, Uyl-de Groot, Carin A., Redekop, William K.
Publicado 2021

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals

por Polak, Tobias B, Cucchi, David GJ, van Rosmalen, Joost, Uyl-de Groot, Carin A
Publicado 2022

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment

por Uyl‐de Groot, Carin A., Ramsden, Rachel, Lee, Dawn, Boersma, Janneke, Zweegman, Sonja, Dhanasiri, Sujith
Publicado 2020

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

por Uyl-de Groot, Carin A., van Rooijen, Elisabeth M., Punt, Cornelis J. A., Pescott, Chris P.
Publicado 2018

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran

por Ansaripour, Amir, Zendehdel, Kazem, Tadayon, Niki, Sadeghi, Fatemeh, Uyl-de Groot, Carin A., Redekop, W. Ken
Publicado 2018

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

por Holleman, Marscha S, van Tinteren, Harm, Groen, Harry JM, Al, Maiwenn J, Uyl-de Groot, Carin A
Publicado 2019

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

por Holleman, Marscha S., Al, Maiwenn J., Zaim, Remziye, Groen, Harry J. M., Uyl-de Groot, Carin A.
Publicado 2019

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review

por Chen, Yi Hsuan, Molenaar, Dominique, Uyl-de Groot, Carin A., van Vulpen, Marco, Blommestein, Hedwig M.
Publicado 2022

Cost-Effectiveness of Hypothetical New Cancer Drugs in Patients with Advanced Small-Cell Lung Cancer: Results of a Markov Chain Model

por Uyl-de Groot, Carin A, McDonnell, Joseph, ten Velde, Guul, Radice, David, Groen, Harry J M
Publicado 2006

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis

por Rens, Neil E, Uyl-de Groot, Carin A, Goldhaber-Fiebert, Jeremy D, Croda, Julio, Andrews, Jason R
Publicado 2020